A way to stimulate the brain’s natural defense mechanisms in people with Alzheimer’s disease has been discovered by researchers at Université Laval, CHU de Québec and pharmaceutical firm GlaxoSmithKline (GSK): a molecule known as MPL (monophosphoryl lipid A) that stimulates the activity of the brain’s immune cells.
The breakthrough opens the door to developing a treatment for Alzheimer’s disease and a vaccine to prevent the illness.